Inflammatory Cardiomyopathy: Diagnostic and Therapeutical Options

摘要: Strategies for immunosuppressive treatment of chronic inflammatory myocardial diseases are still a controversial issue. This dilemma is unresolved despite the “American Myocarditis Trial ” which, as many other studies before, could not demonstrate any positive therapeutic effects therapy [1]. This, however, due to general unresponsiveness cardiac inflammation therapy, but rather reflects an inappropriate study design, that did select optimal group patients therapy. Histological diagnosis process may have been inaccurate and take into consideration spontaneous course disease or possible viral persistence [2–8]. Though prerequisites diagnosing virus-induced considerably improved by new diagnostic techniques in recent years, there yet prospective randomized with precisely characterized patient populations. Ultimately decisive development adequate strategies, precise clinical evaluation be treated. Besides documenting status, it extremely important differentially analyze reaction tissue histological, immunohistological molecular-biological [8]. The histological particularly accurately detect both acute [9,10]. New highly sensitive methods such situ hybridization polymerase chain (PCR) now genome (e.g., enteroviruses) even latent infection restricted replication [11–15]. Only these differential diagnostics enable characterization process, which prerequisite appropriate selection treatment.